{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:16:42Z","timestamp":1789611402808,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cell Biol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41556-026-01925-9","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:03:28Z","timestamp":1774861408000},"page":"957-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reinvigorating COTL1high NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours"],"prefix":"10.1038","volume":"28","author":[{"given":"Wenhua","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chupeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhou","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6657-2760","authenticated-orcid":false,"given":"Bin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-7186","authenticated-orcid":false,"given":"Xiao-Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7001-5908","authenticated-orcid":false,"given":"Qing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-8595","authenticated-orcid":false,"given":"Wei","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-9717","authenticated-orcid":false,"given":"Dong-Ming","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4118-362X","authenticated-orcid":false,"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1925_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"HD Kim","year":"2024","unstructured":"Kim, H. D. et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat. Med. 30, 699\u2013707 (2024).","journal-title":"Nat. Med."},{"key":"1925_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2025","unstructured":"Li, C. et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J. Clin. Oncol. 43, 464\u2013474 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1925_CR3","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053\u20132061 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1925_CR4","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(24)00457-1","volume":"25","author":"A D\u2019Alessio","year":"2024","unstructured":"D\u2019Alessio, A. et al. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. Lancet Oncol. 25, 1465\u20131475 (2024).","journal-title":"Lancet Oncol."},{"key":"1925_CR5","doi-asserted-by":"publisher","first-page":"e169823","DOI":"10.1172\/JCI169823","volume":"133","author":"C Valero","year":"2023","unstructured":"Valero, C. et al. Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. J. Clin. Invest. 133, e169823 (2023).","journal-title":"J. Clin. Invest."},{"key":"1925_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell 38, 685\u2013700 (2020).","journal-title":"Cancer Cell"},{"key":"1925_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature 610, 173\u2013181 (2022).","journal-title":"Nature"},{"key":"1925_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"1925_CR9","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu, S. S. et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 11, 1524\u20131541 (2021).","journal-title":"Cancer Discov."},{"key":"1925_CR10","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186, 3903\u20133920 (2023).","journal-title":"Cell"},{"key":"1925_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","volume":"613","author":"NL de Vries","year":"2023","unstructured":"de Vries, N. L. et al. \u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613, 743\u2013750 (2023).","journal-title":"Nature"},{"key":"1925_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-024-07054-3","volume":"627","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. Deep whole-genome analysis of 494 hepatocellular carcinomas. Nature 627, 586\u2013593 (2024).","journal-title":"Nature"},{"key":"1925_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29203-w","volume":"13","author":"RM Pyke","year":"2022","unstructured":"Pyke, R. M. et al. A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity. Nat. Commun. 13, 1925 (2022).","journal-title":"Nat. Commun."},{"key":"1925_CR14","doi-asserted-by":"publisher","first-page":"e20241442","DOI":"10.1084\/jem.20241442","volume":"222","author":"JMN Teo","year":"2025","unstructured":"Teo, J. M. N. et al. Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma. J. Exp. Med. 222, e20241442 (2025).","journal-title":"J. Exp. Med."},{"key":"1925_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47420-3","volume":"15","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial. Nat. Commun. 15, 3260 (2024).","journal-title":"Nat. Commun."},{"key":"1925_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","volume":"178","author":"JL Benci","year":"2019","unstructured":"Benci, J. L. et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell 178, 933\u2013948 (2019).","journal-title":"Cell"},{"key":"1925_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott, M. M., Jacobs, M. T. & Fehniger, T. A. Allogeneic natural killer cell therapy. Blood 141, 856\u2013868 (2023).","journal-title":"Blood"},{"key":"1925_CR18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41590-022-01315-x","volume":"23","author":"J Dubrot","year":"2022","unstructured":"Dubrot, J. et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat. Immunol. 23, 1495\u20131506 (2022).","journal-title":"Nat. Immunol."},{"key":"1925_CR19","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41590-023-01462-9","volume":"24","author":"X Zheng","year":"2023","unstructured":"Zheng, X. et al. Tumors evade immune cytotoxicity by altering the surface topology of NK cells. Nat. Immunol. 24, 802\u2013813 (2023).","journal-title":"Nat. Immunol."},{"key":"1925_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41590-022-01394-w","volume":"24","author":"SC Oh","year":"2023","unstructured":"Oh, S. C. et al. NgR1 is an NK cell inhibitory receptor that destabilizes the immunological synapse. Nat. Immunol. 24, 463\u2013473 (2023).","journal-title":"Nat. Immunol."},{"key":"1925_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adh2456","volume":"16","author":"N Paillon","year":"2023","unstructured":"Paillon, N. et al. PD-1 inhibits T cell actin remodeling at the immunological synapse independently of its signaling motifs. Sci. Signal. 16, eadh2456 (2023).","journal-title":"Sci. Signal."},{"key":"1925_CR22","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1073\/pnas.1314975111","volume":"111","author":"EM Mace","year":"2014","unstructured":"Mace, E. M. & Orange, J. S. Lytic immune synapse function requires filamentous actin deconstruction by coronin 1A. Proc. Natl Acad. Sci. USA 111, 6708\u20136713 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1925_CR23","doi-asserted-by":"publisher","first-page":"e85090","DOI":"10.1371\/journal.pone.0085090","volume":"9","author":"J Kim","year":"2014","unstructured":"Kim, J. et al. Coactosin-like 1 antagonizes cofilin to promote lamellipodial protrusion at the immune synapse. PLoS ONE 9, e85090 (2014).","journal-title":"PLoS ONE"},{"key":"1925_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43381-1","volume":"14","author":"S Cappuyns","year":"2023","unstructured":"Cappuyns, S. et al. PD-1\u2212 CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat. Commun. 14, 7825 (2023).","journal-title":"Nat. Commun."},{"key":"1925_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15816-6","volume":"11","author":"B Jew","year":"2020","unstructured":"Jew, B. et al. Accurate estimation of cell composition in bulk expression through robust integration of single-cell information. Nat. Commun. 11, 1971 (2020).","journal-title":"Nat. Commun."},{"key":"1925_CR26","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","volume":"186","author":"F Tang","year":"2023","unstructured":"Tang, F. et al. A pan-cancer single-cell panorama of human natural killer cells. Cell 186, 4235\u20134251 (2023).","journal-title":"Cell"},{"key":"1925_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101511","volume":"5","author":"L Xu","year":"2024","unstructured":"Xu, L. et al. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response. Cell Rep. Med. 5, 101511 (2024).","journal-title":"Cell Rep. Med."},{"key":"1925_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn0164","volume":"10","author":"K Pouxvielh","year":"2024","unstructured":"Pouxvielh, K. et al. Tumor-induced natural killer cell dysfunction is a rapid and reversible process uncoupled from the expression of immune checkpoints. Sci. Adv. 10, eadn0164 (2024).","journal-title":"Sci. Adv."},{"key":"1925_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-2567.2011.03446.x","volume":"133","author":"B Fu","year":"2011","unstructured":"Fu, B. et al. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology 133, 350\u2013359 (2011).","journal-title":"Immunology"},{"key":"1925_CR30","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1925_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2017.09.052","volume":"171","author":"OE Weizman","year":"2017","unstructured":"Weizman, O. E. et al. ILC1 confer early host protection at initial sites of viral infection. Cell 171, 795\u2013808 (2017).","journal-title":"Cell"},{"key":"1925_CR32","first-page":"753","volume":"46","author":"L Mackay","year":"2016","unstructured":"Mackay, L. et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue-residency in lymphocytes. Eur. J. Immunol. 46, 753\u2013753 (2016).","journal-title":"Eur. J. Immunol."},{"key":"1925_CR33","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","volume":"82","author":"S Cappuyns","year":"2025","unstructured":"Cappuyns, S. et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J. Hepatol. 82, 1036\u20131049 (2025).","journal-title":"J. Hepatol."},{"key":"1925_CR34","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1136\/gutjnl-2021-326350","volume":"71","author":"LG Lu","year":"2022","unstructured":"Lu, L. G. et al. PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma. Gut 71, 2551\u20132560 (2022).","journal-title":"Gut"},{"key":"1925_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri2526","volume":"9","author":"M Croft","year":"2009","unstructured":"Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271\u2013285 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1925_CR36","doi-asserted-by":"publisher","first-page":"7925","DOI":"10.1093\/nar\/gkac601","volume":"50","author":"T Friedrich","year":"2022","unstructured":"Friedrich, T. et al. Notch-dependent and -independent functions of transcription factor RBPJ. Nucleic Acids Res. 50, 7925\u20137937 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1925_CR37","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1136\/gutjnl-2024-332225","volume":"73","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. Pancreatic STAT5 activation promotes KrasG12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Gut 73, 1831\u20131843 (2024).","journal-title":"Gut"},{"key":"1925_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10023-4","volume":"10","author":"N Jones","year":"2019","unstructured":"Jones, N. et al. Akt and STAT5 mediate naive human CD4+ T-cell early metabolic response to TCR stimulation. Nat. Commun. 10, 2042 (2019).","journal-title":"Nat. Commun."},{"key":"1925_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41568-022-00543-5","volume":"23","author":"DA Guertin","year":"2023","unstructured":"Guertin, D. A. & Wellen, K. E. Acetyl-CoA metabolism in cancer. Nat. Rev. Cancer 23, 156\u2013172 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1925_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42748-8","volume":"14","author":"CM Young","year":"2023","unstructured":"Young, C. M. et al. Metabolic dependencies of metastasis-initiating cells in female breast cancer. Nat. Commun. 14, 7076 (2023).","journal-title":"Nat. Commun."},{"key":"1925_CR41","first-page":"A345","volume":"15","author":"Y Latchman","year":"2001","unstructured":"Latchman, Y. et al. PD-L2, a novel B7 homologue, is a second ligand for PD-1 and inhibits T cell activation. FASEB J. 15, A345 (2001).","journal-title":"FASEB J."},{"key":"1925_CR42","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka, T. et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209, 1201\u20131217 (2012).","journal-title":"J. Exp. Med."},{"key":"1925_CR43","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"XY Hu","year":"2021","unstructured":"Hu, X. Y., Li, J., Fu, M. R., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct. Target. Ther. 6, 402 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1925_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","volume":"40","author":"NS Patil","year":"2022","unstructured":"Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 40, 289\u2013300 (2022).","journal-title":"Cancer Cell"},{"key":"1925_CR45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282\u2013296 (2019).","journal-title":"Lancet Oncol."},{"key":"1925_CR46","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/0008-5472.CAN-23-0966","volume":"84","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma. Cancer Res. 84, 855\u2013871 (2024).","journal-title":"Cancer Res."},{"key":"1925_CR47","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1136\/gutjnl-2020-322196","volume":"70","author":"T Liu","year":"2021","unstructured":"Liu, T. et al. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells. Gut 70, 1965\u20131977 (2021).","journal-title":"Gut"},{"key":"1925_CR48","doi-asserted-by":"publisher","first-page":"eabq7248","DOI":"10.1126\/science.abq7248","volume":"386","author":"A Hayday","year":"2024","unstructured":"Hayday, A., Dechanet-Merville, J., Rossjohn, J. & Silva-Santos, B. Cancer immunotherapy by \u03b3\u03b4 T cells. Science 386, eabq7248 (2024).","journal-title":"Science"},{"key":"1925_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm9043","volume":"14","author":"N Kirchhammer","year":"2022","unstructured":"Kirchhammer, N. et al. NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Sci. Transl. Med. 14, eabm9043 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1925_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/2326-6066.CIR-24-0124","volume":"13","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. CD49a targeting enhances NK cell function and antitumor immunity. Cancer Immunol. Res. 13, 139\u2013151 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"1925_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64531-7","volume":"16","author":"M Vermeer","year":"2025","unstructured":"Vermeer, M. et al. Tissue localization of natural killer cells dictates surveillance of lung metastasis. Nat. Commun. 16, 9464 (2025).","journal-title":"Nat. Commun."},{"key":"1925_CR52","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","volume":"187","author":"YL Li","year":"2024","unstructured":"Li, Y. L. et al. IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell 187, 2703\u20132716 (2024).","journal-title":"Cell"},{"key":"1925_CR53","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ccell.2024.05.006","volume":"42","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer Cell 42, 985\u20131002 (2024).","journal-title":"Cancer Cell"},{"key":"1925_CR54","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00262-010-0866-5","volume":"59","author":"D Coe","year":"2010","unstructured":"Coe, D. et al. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol. Immunother. 59, 1367\u20131377 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"1925_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101420","volume":"5","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. Cell Rep. Med. 5, 101420 (2024).","journal-title":"Cell Rep. Med."},{"key":"1925_CR56","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.immuni.2024.05.021","volume":"57","author":"RB Delconte","year":"2024","unstructured":"Delconte, R. B. et al. Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity. Immunity 57, 1923\u20131938 (2024).","journal-title":"Immunity"},{"key":"1925_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1090311","volume":"14","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. The application of interleukin-2 family cytokines in tumor immunotherapy research. Front. Immunol. 14, 1090311 (2023).","journal-title":"Front. Immunol."},{"key":"1925_CR58","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."},{"key":"1925_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","volume":"5","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy. Nat. Cancer 5, 167\u2013186 (2024).","journal-title":"Nat. Cancer"},{"key":"1925_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46413-6","volume":"15","author":"ZX Zhong","year":"2024","unstructured":"Zhong, Z. X. et al. Domain generalization enables general cancer cell annotation in single-cell and spatial transcriptomics. Nat. Commun. 15, 1929 (2024).","journal-title":"Nat. Commun."},{"key":"1925_CR61","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"1925_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13059-020-1949-z","volume":"21","author":"CH Holland","year":"2020","unstructured":"Holland, C. H. et al. Robustness and applicability of transcription factor and pathway analysis tools on single-cell RNA-seq data. Genome Biol. 21, 36 (2020).","journal-title":"Genome Biol."},{"key":"1925_CR63","doi-asserted-by":"publisher","first-page":"eaba6232","DOI":"10.1126\/sciimmunol.aba6232","volume":"5","author":"V Stary","year":"2020","unstructured":"Stary, V. et al. A discrete subset of epigenetically primed human NK cells mediates antigen-specific immune responses. Sci. Immunol. 5, eaba6232 (2020).","journal-title":"Sci. Immunol."},{"key":"1925_CR64","doi-asserted-by":"publisher","first-page":"eabi8642","DOI":"10.1126\/sciimmunol.abi8642","volume":"7","author":"BG Nixon","year":"2022","unstructured":"Nixon, B. G. et al. Cytotoxic granzyme C-expressing ILC1s contribute to antitumor immunity and neonatal autoimmunity. Sci. Immunol. 7, eabi8642 (2022).","journal-title":"Sci. Immunol."},{"key":"1925_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09982-5","volume":"10","author":"HS Kaya-Okur","year":"2019","unstructured":"Kaya-Okur, H. S. et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat. Commun. 10, 1930 (2019).","journal-title":"Nat. Commun."},{"key":"1925_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25957-x","volume":"12","author":"JB Kang","year":"2021","unstructured":"Kang, J. B. et al. Efficient and precise single-cell reference atlas mapping with Symphony. Nat. Commun. 12, 5890 (2021).","journal-title":"Nat. Commun."},{"key":"1925_CR67","doi-asserted-by":"publisher","first-page":"821542","DOI":"10.3389\/fimmu.2022.821542","volume":"13","author":"X Du","year":"2022","unstructured":"Du, X. et al. Human-induced CD49a+ NK cells promote fetal growth. Front. Immunol. 13, 821542 (2022).","journal-title":"Front. Immunol."},{"key":"1925_CR68","doi-asserted-by":"publisher","first-page":"e2101169118","DOI":"10.1073\/pnas.2101169118","volume":"118","author":"UY Moreno-Nieves","year":"2021","unstructured":"Moreno-Nieves, U. Y. et al. Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment. Proc. Natl Acad. Sci. USA 118, e2101169118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Cell Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41556-026-01925-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41556-026-01925-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41556-026-01925-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:02:41Z","timestamp":1778857361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41556-026-01925-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1925"],"URL":"https:\/\/doi.org\/10.1038\/s41556-026-01925-9","relation":{},"ISSN":["1465-7392","1476-4679"],"issn-type":[{"value":"1465-7392","type":"print"},{"value":"1476-4679","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}